191 related articles for article (PubMed ID: 36332161)
21. Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial.
Park SJ; Shim SH; Ji YI; Kwon SH; Lee EJ; Lee M; Chang SJ; Park S; Kim SY; Lee SJ; Kim JW; Roh JW; Lee SH; Song T; Kim HS
BMC Cancer; 2020 May; 20(1):385. PubMed ID: 32375688
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of sequential chemotherapy efficacy in ovarian epithelial carcinoma, fallopian tube carcinoma and primary peritoneal carcinoma].
Shen XY; Li XP; Wang Y; Wu Y; Li Y; Yang YC; Wei LH; Fan Y; Tang ZQ
Zhonghua Fu Chan Ke Za Zhi; 2024 May; 59(5):383-390. PubMed ID: 38797568
[No Abstract] [Full Text] [Related]
23. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Burger RA; Brady MF; Rhee J; Sovak MA; Kong G; Nguyen HP; Bookman MA
Gynecol Oncol; 2013 Oct; 131(1):21-6. PubMed ID: 23906656
[TBL] [Abstract][Full Text] [Related]
24. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
25. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
González Martín A; Oza AM; Embleton AC; Pfisterer J; Ledermann JA; Pujade-Lauraine E; Kristensen G; Bertrand MA; Beale P; Cervantes A; Kent E; Kaplan RS; Parmar MKB; Scotto N; Perren TJ;
Gynecol Oncol; 2019 Jan; 152(1):53-60. PubMed ID: 30449719
[TBL] [Abstract][Full Text] [Related]
26. Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Burger RA; Brady MF; Bookman MA; Fleming GF; Monk BJ; Huang H; Mannel RS; Homesley HD; Fowler J; Greer BE; Boente M; Birrer MJ; Liang SX;
N Engl J Med; 2011 Dec; 365(26):2473-83. PubMed ID: 22204724
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Daniele G; Raspagliesi F; Scambia G; Pisano C; Colombo N; Frezzini S; Tognon G; Artioli G; Gadducci A; Lauria R; Ferrero A; Cinieri S; De Censi A; Breda E; Scollo P; De Giorgi U; Lissoni AA; Katsaros D; Lorusso D; Salutari V; Cecere SC; Zaccarelli E; Nardin M; Bogani G; Distefano M; Greggi S; Piccirillo MC; Fossati R; Giannone G; Arenare L; Gallo C; Perrone F; Pignata S
Int J Gynecol Cancer; 2021 Jun; 31(6):875-882. PubMed ID: 33931498
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial.
Falandry C; Rousseau F; Mouret-Reynier MA; Tinquaut F; Lorusso D; Herrstedt J; Savoye AM; Stefani L; Bourbouloux E; Sverdlin R; D'Hondt V; Lortholary A; Brachet PE; Zannetti A; Malaurie E; Venat-Bouvet L; Trédan O; Mourey L; Pujade-Lauraine E; Freyer G;
JAMA Oncol; 2021 Jun; 7(6):853-861. PubMed ID: 33885718
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
Rob L; Cibula D; Knapp P; Mallmann P; Klat J; Minar L; Bartos P; Chovanec J; Valha P; Pluta M; Novotny Z; Spacek J; Melichar B; Kieszko D; Fucikova J; Hrnciarova T; Korolkiewicz RP; Hraska M; Bartunkova J; Spisek R
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34992091
[TBL] [Abstract][Full Text] [Related]
31. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Gordon AN; Teneriello M; Janicek MF; Hines J; Lim PC; Chen MD; Vaccarello L; Homesley HD; McMeekin S; Burkholder TL; Wang Y; Zhao L; Orlando M; Obasaju CK; Gill JF; Tai DF
Gynecol Oncol; 2011 Dec; 123(3):479-85. PubMed ID: 21978765
[TBL] [Abstract][Full Text] [Related]
32. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Kurtz JE; Pujade-Lauraine E; Oaknin A; Belin L; Leitner K; Cibula D; Denys H; Rosengarten O; Rodrigues M; de Gregorio N; Martinez García J; Petru E; Kocián R; Vergote I; Pautier P; Schmalfeldt B; Gaba L; Polterauer S; Mouret Reynier MA; Sehouli J; Churruca C; Selle F; Joly F; D'Hondt V; Bultot-Boissier É; Lebreton C; Lotz JP; Largillier R; Heudel PE; Heitz F;
J Clin Oncol; 2023 Oct; 41(30):4768-4778. PubMed ID: 37643382
[TBL] [Abstract][Full Text] [Related]
33. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Tewari KS; Burger RA; Enserro D; Norquist BM; Swisher EM; Brady MF; Bookman MA; Fleming GF; Huang H; Homesley HD; Fowler JM; Greer BE; Boente M; Liang SX; Ye C; Bais C; Randall LM; Chan JK; Ferriss JS; Coleman RL; Aghajanian C; Herzog TJ; DiSaia PJ; Copeland LJ; Mannel RS; Birrer MJ; Monk BJ
J Clin Oncol; 2019 Sep; 37(26):2317-2328. PubMed ID: 31216226
[TBL] [Abstract][Full Text] [Related]
34. Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer.
Vergote IB; Chekerov R; Amant F; Harter P; Casado A; Emerich J; Bauknecht T; Mansouri K; Myrand SP; Nguyen TS; Shi P; Sehouli J
J Clin Oncol; 2013 Sep; 31(25):3127-32. PubMed ID: 23897968
[TBL] [Abstract][Full Text] [Related]
35. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
36. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
[TBL] [Abstract][Full Text] [Related]
37. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
38. Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
Colombo N; Van Gorp T; Matulonis UA; Oaknin A; Grisham RN; Fleming GF; Olawaiye AB; Nguyen DD; Greenstein AE; Custodio JM; Pashova HI; Tudor IC; Lorusso D
J Clin Oncol; 2023 Oct; 41(30):4779-4789. PubMed ID: 37364223
[TBL] [Abstract][Full Text] [Related]
39. Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial.
Chou HH; Chen WC; Yang LY; Huang HJ; Chang WY; Lin H; Wu RC; Chen MY; Qiu JT; Huang KG; Chao A; Chang TC; Lai CH
Eur J Obstet Gynecol Reprod Biol; 2021 Jul; 262():13-20. PubMed ID: 33984725
[TBL] [Abstract][Full Text] [Related]
40. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]